News | January 11, 2010

SRS Reirradiation for Head-and-Neck Cancer Found Feasible

January 11, 2010 - Reirradiation using fractionated stereotactic radiosurgery (SRS) after previous radiotherapy for head-and-neck cancer is feasible, concluded researchers a study published in the Official Journal of the American Society for Radiation Oncology.

The researchers wanted to find the feasibility of stereotactic radiosurgery (SRS) because it “is an appealing treatment option after previous radiotherapy because of its precision, conformality, and reduced treatment duration.”

From 2002 to 2008, 65 patients received SRS to the oropharynx (13), hypopharynx (8), nasopharynx (7), paranasal sinus (7), neck (7), and other sites (23). Thirty-eight patients were treated definitively and 27 patients with metastatic disease and/or untreated local disease were treated palliatively. Nine patients underwent complete macroscopic resection before SRS. Thirty-three patients received concurrent chemoradiation. The median initial radiation dose was 67 Gy, and the median reirradiation SRS dose was 30 Gy (21–35 Gy) in 2–5 fractions.

Follow-up was on average 16 months for surviving patients. Fifty-six patients were evaluable for response: 30 (54 percent) had complete, 15 (27 percent) had partial, and 11 (20 percent) had no response. The overall survival (OS) for all patients averaged 12 months. For definitively treated patients, the 2-year OS and locoregional control (LRC) rates were 41 percent and 30 percent, respectively. Multivariate analysis demonstrated that higher total dose, surgical resection, and nasopharynx site were significantly associated with improved LRC; surgical resection and nonsquamous histology were associated with improved OS. Seven patients (11 percent) experienced severe reirradiation-related toxicity, including one treatment-attributed death.

Researchers concluded their findings showing SRS reirradiation for head-and-neck cancer a feasible demonstrated encouraging response rates with acceptable toxicity.

But they cautioned, “Fractionated SRS reirradiation with concurrent chemotherapy in select patients warrants further study.”

Reference: Unger, M.D., K.; Lominska, M.D., C.; Deeken, M.D., J.; et al. Fractionated Stereotactic Radiosurgery for Reirradiation of Head-and-Neck Cancer. doi:10.1016/j.ijrobp.2009.06.070

For more information: www.redjournal.org

Related Content

Members of Congress from both sides of the aisle issued a series of oversight letters to the Centers for Medicare and Medicaid Services (CMS) in recent months to urge the Agency to adjust its proposed radiation oncology advanced alternative payment model (RO Model)

Image by whitfieldink from Pixabay

News | Radiation Oncology | November 13, 2019
November 13, 2019 — Members of Congress from both sides of the aisle issued a series of oversight letters to the...
Bladder Abdomen Pelvis image with DLCExpert
News | Artificial Intelligence | November 07, 2019
November 7, 2019 — Mirada Medical, a global leader in...
Liver cancer tumor scanning using an MRI
News | Proton Therapy | November 04, 2019
November 4, 2019 – Two new studies support and inform the use of proton radiation therapy to treat patients with hepa
Advanced Radiation Therapy Upgrades AccuBoost Digital Brachytherapy Platform
News | Brachytherapy Systems, Women's Healthcare | October 23, 2019
At the 2019 American Society for Radiation Oncology (ASTRO) annual meeting, Sept. 15-18 in Chicago, Advanced Radiation...
MD Anderson and Varian Partner to Optimize Radiation Oncology Treatment
News | Treatment Planning | October 18, 2019
The University of Texas MD Anderson Cancer Center and Varian announced a new strategic collaboration to develop an...
Low four-year rates of gastrointestinal (13.6 percent) and urologic issues (7.6 percent) suggest hypofractionated proton therapy as an alternative to traditional radiotherapy to reduce toxicity.

Low four-year rates of gastrointestinal (13.6 percent) and urologic issues (7.6 percent) suggest hypofractionated proton therapy as an alternative to traditional radiotherapy to reduce toxicity.

Feature | Prostate Cancer | October 16, 2019 | By Jeff Zagoudis
Radiation therapy is an important tool in the clinician’s armamentarium for treatment of localized, early-stage prost
Videos | Radiation Oncology | October 11, 2019
Lorraine Drapek, DNP, nurse practitioner, radiation oncology, GI service,...